Unichem Laboratories Upgraded to 'Hold' Status

Unichem Laboratories, a smallcap pharmaceutical company, has recently been upgraded to a 'Hold' by MarketsMOJO on December 15, 2023. The stock is currently in a bullish range and the technical trend has improved from mildly bullish to bullish. This is supported by multiple factors such as RSI, MACD, Bollinger Band, KST, and OBV. One of the reasons for this upgrade is the rising confidence of the promoters in the company. They have increased their stake by 19.28% in the previous quarter and currently hold 70.21% of the company. This is a positive sign as it shows their belief in the future of the business. However, there are some concerns that investors should be aware of. The company has a high debt to EBITDA ratio of -1.00 times, indicating a low ability to service debt. Additionally, the company has shown poor long-term growth with net sales growing at an annual rate of 5.55% and operating profit at 1.17% over the last 5 years. This is further reflected in the low return on equity of 0.52%. In the latest quarter, the company's results were flat with the lowest cash and cash equivalents at Rs 64.56 crore and the highest interest at Rs 6.73 crore. This could be a cause for concern for investors. Moreover, the stock is currently trading at a risky level compared to its average historical valuations. While it has generated a return of 29.82% in the past year, its profits have fallen by -215.4%. This highlights the negative operating profits of the company. In conclusion, while Unichem Laboratories has shown some positive signs with the recent upgrade to a 'Hold', investors should also consider the risks and concerns associated with the company before making any investment decisions.